Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) Research & Development (2016 - 2025)

Historic Research & Development for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to $86.8 million.

  • Agios Pharmaceuticals' Research & Development rose 1979.3% to $86.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $334.3 million, marking a year-over-year increase of 1294.88%. This contributed to the annual value of $301.3 million for FY2024, which is 194.91% up from last year.
  • Per Agios Pharmaceuticals' latest filing, its Research & Development stood at $86.8 million for Q3 2025, which was up 1979.3% from $91.9 million recorded in Q2 2025.
  • Over the past 5 years, Agios Pharmaceuticals' Research & Development peaked at $91.9 million during Q2 2025, and registered a low of $57.7 million during Q1 2021.
  • For the 5-year period, Agios Pharmaceuticals' Research & Development averaged around $72.9 million, with its median value being $72.5 million (2024).
  • Within the past 5 years, the most significant YoY rise in Agios Pharmaceuticals' Research & Development was 24395.78% (2021), while the steepest drop was 3680.74% (2021).
  • Over the past 5 years, Agios Pharmaceuticals' Research & Development (Quarter) stood at $73.3 million in 2021, then fell by 4.09% to $70.3 million in 2022, then rose by 10.23% to $77.5 million in 2023, then rose by 6.87% to $82.8 million in 2024, then increased by 4.81% to $86.8 million in 2025.
  • Its Research & Development was $86.8 million in Q3 2025, compared to $91.9 million in Q2 2025 and $72.7 million in Q1 2025.